Ampio pharmaceuticals, inc. (AMPE)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Cash flows from operating activities
Net (loss) income

-12,997

-13,630

-11,084

1,935

6,134

33,986

-10,665

-20,719

-27,948

-51,891

-12,120

-11,859

-14,303

-19,163

-26,431

-30,225

-32,887

-33,713

-33,244

-34,949

-36,168

-39,048

0

0

0

Adjustments to reconcile net (loss) income to net cash used in operating activities
Stock-based compensation, net

590

405

503

352

352

444

349

560

659

744

836

973

1,074

1,516

2,662

3,091

4,459

4,957

5,710

7,335

7,300

7,176

0

0

0

Depreciation and amortization

1,202

1,272

1,288

1,395

1,345

1,281

1,271

1,228

1,211

1,214

1,208

1,210

1,212

1,214

1,123

1,023

923

824

0

0

0

-

-

0

0

Write-off of advances to stockholder

-

-

-

-

-

-

-

-

-

25

25

25

25

0

0

0

0

-

-

-

-

-

-

-

-

Amortization of prepaid research and development - related party (Note 9)

-

-

-

-

-

-

-

-

-

323

359

395

143

143

143

143

143

143

77

108

138

113

0

0

0

Issuance of common stock for services

100

80

60

60

60

60

60

60

60

60

60

60

60

60

60

60

60

30

30

30

30

30

0

0

0

Derivative loss (gain)

8,860

4,869

2,954

12,753

16,523

45,298

2,799

-6,092

-11,731

-36,218

1,893

2,324

211

-915

0

0

0

-

-

-

-

-

-

-

-

Loss on equity investment in Aytu BioSciences, Inc.

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,043

0

0

0

-

-

-

-

-

-

-

-

Unrealized loss on trading security in Aytu BioScience, Inc.

-

-

-

-

-

-

-

-

-

-

-

-

-176

-146

0

0

0

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities
(Increase) decrease in prepaid expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

0

0

Increase in prepaid expenses and other

393

1,271

1,289

1,311

206

179

69

-446

-211

-129

-50

41

81

-80

0

0

0

-

-

-

-

-

-

-

-

Increase (decrease) in accounts payable and accrued expenses

2,894

2,700

464

-1,329

-2,207

-2,495

-396

347

1,727

2,076

-119

458

-1,445

-1,095

0

0

0

-

-

-

-

-

-

-

-

Decrease in lease liability

-32

-70

-68

-146

-103

-61

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Increase in prepaid research and development - related party (Note 11)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Decrease in accounts payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

0

0

0

Increase in accrued liabilities - related party (Note 7)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Decrease in deferred rent

-

-

-

-

-

-

-

-

-

50

48

46

43

41

38

36

34

31

0

0

0

-

-

-

-

(Decrease) increase in deferred revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Increase (decrease) in accrued compensation

-

-

-

-

-

-

-

-276

-321

-332

-21

80

263

480

382

445

602

744

823

700

438

-380

0

0

0

Net cash used in operating activities - continuing operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-17,900

-18,094

-18,446

-22,379

-23,380

0

0

0

Net cash used in operating activities - discontinuing operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-8,543

0

0

0

-

-

-

-

Net cash used in operating activities

-17,496

-15,383

-12,958

-11,430

-10,974

-12,139

-12,384

-12,303

-12,390

-11,407

0

0

0

-

-

-

-24,321

-26,444

0

0

0

-

-

-

-

Cash flows used in investing activities
Purchase of fixed assets

17

22

92

135

380

564

524

497

243

72

40

24

24

6

1

26

67

110

851

2,853

5,669

8,668

0

0

0

Net cash used in investing activities - continuing operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-16,289

-6,372

-8,362

-11,177

-14,176

0

0

0

Net cash used in investing activities - discontinuing operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,786

0

0

0

-

-

-

-

Net cash used in investing activities

-17

-22

-92

-135

-380

-564

-524

-497

-243

-72

0

0

0

-

-

-

-18,033

-18,076

0

0

0

-

-

-

-

Cash flows from financing activities
Proceeds from sale of common stock in connection with the equity distribution agreement

824

142

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Costs related to sale of common stock in connection with the equity distribution agreement

390

144

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gross proceeds from issuance of common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Costs related to sale of common stock related to the confidentially marketed public offering

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Proceeds from warrant exercises

3,854

3,874

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from option and warrant exercises

-

-

-

-

-

-

-

-

5,907

2,806

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities - continuing operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-33

63,409

0

0

0

Net cash provided by financing activities - discontinuing operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

21,129

0

0

0

-

-

-

-

Net cash provided by financing activities

14,768

14,352

12,422

19,687

8,998

12,079

19,773

12,521

17,895

14,794

0

0

0

-

-

-

21,157

21,157

0

0

0

-

-

-

-

Net change in cash and cash equivalents

-2,745

-1,053

-628

8,121

-2,357

-624

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net change in cash and cash equivalents

-

-

-

-

-

-

-

-

-

3,314

-5,609

-1,511

-8,858

-11,103

-17,008

-19,372

-21,197

-23,362

-21,445

-28,851

-34,954

24,011

0

0

0

Non-cash transactions:
Initial lease liability arising from the adoption of ASU 2016-02

0

1,704

1,704

1,704

1,704

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Initial recognition of right-of-use asset arising from the adoption of ASU 2016-02

0

1,168

1,167

1,167

1,168

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Fixed asset purchases included in accounts payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

Distribution to stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

13,018

0

0

0

-

-

-

-

-

-

-

-